Screening period to be shortened over salt-modified medicines
Published: 2008-03-17 06:57:00
Updated: 2008-03-17 06:57:00
The Health Insurance Review & Assessment Service said it will revise rules to shorten the screening period of salt- or dosage form-modified drugs to a period of 60-90 days, down from the current 150 days, in a move aimed at improving its national efficiency.
We can be able to simplify the eval...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
